Literature DB >> 21498368

Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results.

Nami Choi1, Won-Jin Moon, Jeong Hyun Lee, Jung Hwan Baek, Dong Wook Kim, Sun-Won Park.   

Abstract

BACKGROUND: Complete initial tumor resection is a key prognostic factor in patients with medullary thyroid carcinomas (MTCs), hence precise preoperative diagnosis is very important. Thyroid ultrasonography (US) is a first-line modality and can lead to the appropriate next diagnostic procedure.
PURPOSE: To evaluate the US characteristics of MTCs, to evaluate whether or not there is a difference in US findings according to tumor size, and to correlate the US findings with fine needle aspiration (FNA) results.
MATERIAL AND METHODS: Thirty patients with 36 MTCs who had a preoperative US and a MTC diagnosis based on surgery were included. The US findings of each nodule were retrospectively analyzed in terms of size, internal content, shape, margin, echogenicity of solid portions, the presence of calcifications, the type of calcifications, and the presence of a halo by two radiologists. Each lesion was classified as suspiciously malignant, indeterminate, or probably benign according to known US criteria. The FNA results for the 28 MTCs were reviewed from the cytology reports.
RESULTS: The lesion size varied from 5.7-90.0 mm (mean 22.4 ± 14.4 mm). The predominate US findings included solid internal content (91.7%), round-to-oval shape (63.9%), smooth margins (52.8%), hypoechogenicity (72.2%), and micro- or macro-calcifications (61.1%). Twenty-six nodules (72.2%) were classified as suspiciously malignant, and 10 nodules (27.8%) were classified as indeterminate. Of the 27 MTCs classified as suspiciously malignant, 21 MTCs (77.8%) had micro- or macro-calcifications, which was the most common malignant feature. MicroMTCs (≤1 cm) had spiculated margins more frequently than macroMTCs (66.7% vs. 13.3%; P = 0.014) and macroMTCs (>1 cm) had smooth margins more frequently than microMTCs (63.4% vs. 0%; P = 0.006). Twenty-one MTCs with positive FNA results showed smooth margins and a larger size more frequently than seven MTCs with negative FNA results (66.7% vs. 14.3%; P = 0.029; mean diameter, 24.28 ± 13.45 mm vs. 11.74 ± 4.73 mm, P = 0.004, respectively).
CONCLUSION: Based on US, the majority of MTCs can be classified as suspiciously malignant due to the presence of micro- or macro-calcifications. Small MTC size (≤ 10 mm) and a smooth margin may be factors predicting false-negative FNA results.

Entities:  

Mesh:

Year:  2011        PMID: 21498368     DOI: 10.1258/ar.2010.100247

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  14 in total

Review 1.  [Imaging of medullary thyroid carcinoma].

Authors:  M Uhrig; S Delorme
Journal:  Radiologe       Date:  2019-11       Impact factor: 0.635

Review 2.  Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.

Authors:  C M Thomas; S L Asa; S Ezzat; A M Sawka; D Goldstein
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

3.  Ultrasonography should not guide the timing of thyroidectomy in pediatric patients diagnosed with multiple endocrine neoplasia syndrome 2A through genetic screening.

Authors:  Lilah F Morris; Steven G Waguespack; Beth S Edeiken-Monroe; Jeff E Lee; Thereasa A Rich; Anita K Ying; Carla L Warneke; Douglas B Evans; Nancy D Perrier; Elizabeth G Grubbs
Journal:  Ann Surg Oncol       Date:  2012-08-14       Impact factor: 5.344

Review 4.  New American Thyroid Association Sonographic Patterns for Thyroid Nodules Perform Well in Medullary Thyroid Carcinoma: Institutional Experience, Systematic Review, and Meta-Analysis.

Authors:  Pablo Valderrabano; Donald L Klippenstein; John B Tourtelot; Zhenjun Ma; Zachary J Thompson; Howard S Lilienfeld; Bryan McIver
Journal:  Thyroid       Date:  2016-07-08       Impact factor: 6.568

5.  Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: a retrospective multicenter study.

Authors:  Pierpaolo Trimboli; Luca Giovanella; Stefano Valabrega; Massimiliano Andrioli; Roberto Baldelli; Nadia Cremonini; Fabio Rossi; Leo Guidobaldi; Agnese Barnabei; Francesca Rota; Antonella Paoloni; Laura Rizza; Giorgio Fattorini; Maurizio Latini; Claudio Ventura; Paolo Falasca; Fabio Orlandi; Anna Crescenzi; Ferdinando D'Ambrosio; Vito Cantisani; Francesco Romanelli; Roberto Negro; Enrico Saggiorato; Marialuisa Appetecchia
Journal:  J Exp Clin Cancer Res       Date:  2014-10-25

6.  Is TIRADS a practical and accurate system for use in daily clinical practice?

Authors:  Anuradha Chandramohan; Abhishek Khurana; B T Pushpa; Marie Therese Manipadam; Dukhabandhu Naik; Nihal Thomas; Deepak Abraham; Mazhuvanchary Jacob Paul
Journal:  Indian J Radiol Imaging       Date:  2016 Jan-Mar

7.  Clinical value of color Doppler ultrasound combined with serum tumor markers for the diagnosis of medullary thyroid carcinoma.

Authors:  Xue Yang; Jinjuan Xu; Jilan Sun; Lizhi Yin; Rui Guo; Zhimei Yan
Journal:  Oncol Lett       Date:  2021-05-27       Impact factor: 2.967

8.  Tumor size interpretation for predicting cervical lymph node metastasis using a differentiated thyroid cancer risk model.

Authors:  Rong-Liang Shi; Ning Qu; Shu-Wen Yang; Ben Ma; Zhong-Wu Lu; Duo Wen; Guo-Hua Sun; Yu Wang; Qing-Hai Ji
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

9.  Hypervascularity is more frequent in medullary thyroid carcinoma: Compared with papillary thyroid carcinoma.

Authors:  Xingjian Lai; Meijuan Liu; Yu Xia; Liang Wang; Yalan Bi; Xiaoyi Li; Bo Zhang; Meng Yang; Qing Dai; Yuxin Jiang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

10.  Clinical and ultrasonographic features of medullary thyroid microcarcinomas compared with papillary thyroid microcarcinomas: a retrospective analysis.

Authors:  Xiaoyu Li; Wei Zhou; Weiwei Zhan
Journal:  BMC Med Imaging       Date:  2020-05-14       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.